TABLE III.
Results of Cox proportional hazards analysis on overall survivala
Variable | hr | 95% ci | p Value | Impact on survival |
---|---|---|---|---|
Line of chemotherapy | 1.39 | 1.05 to 1.84 | 0.021 | ↑ Risk by 39% per line |
Achievement of clinical benefita | 0.14 | 0.06 to 0.33 | 0.001 | ↓ Risk by 86% |
Schedule of nab-paclitaxel was not a significant predictor of overall survival, nor was the interaction between nab-paclitaxel schedule and achievement of clinical benefit.